J
Julio Rosenstock
Researcher at University of Texas Southwestern Medical Center
Publications - 423
Citations - 39792
Julio Rosenstock is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 94, co-authored 364 publications receiving 32784 citations. Previous affiliations of Julio Rosenstock include Medical City Dallas Hospital & Pfizer.
Papers
More filters
Journal ArticleDOI
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P. Marso,Stephen C. Bain,A. Consoli,Freddy G. Eliaschewitz,Esteban Jódar,Lawrence A. Leiter,Ildiko Lingvay,Julio Rosenstock,Jochen Seufert,Mark Warren,Vincent Woo,O Hansen,Anders G. Holst,Jonas Pettersson,Tina Vilsbøll +14 more
TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.
Journal ArticleDOI
The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
TL;DR: Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7% HbA(1c) in a majority of overweight patients with type 2 diabetes, thus reducing a leading barrier to initiating insulin.
Journal ArticleDOI
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B. Buse,Julio Rosenstock,Giorgio Sesti,Wolfgang E. Schmidt,Eduard Montanya,Jason Brett,Marcin Zychma,Lawrence Blonde +7 more
TL;DR: Liraglutide once a day provided significantly greater improvements in glycaemic control than did exenatide twice a day, and was generally better tolerated, suggesting that liragLutide might be a treatment option for type 2 diabetes, especially when weight loss and risk of hypoglycaemia are major considerations.
Journal ArticleDOI
Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial
TL;DR: Treatment with 20 mg/d of rimonabant plus diet for 2 years promoted modest but sustained reductions in weight and waist circumference and favorable changes in cardiometabolic risk factors, however, the trial was limited by a high drop-out rate and longer-term effects of the drug require further study.
Journal ArticleDOI
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
David M. Kendall,Matthew C. Riddle,Julio Rosenstock,Dongliang Zhuang,Dennis Dong Hwan Kim,Mark Fineman,Alain D. Baron +6 more
TL;DR: Exenatide significantly reduced A1C in patients with type 2 diabetes unable to achieve adequate glycemic control with maximally effective doses of combined metformin-sulfonylurea therapy, associated with no weight gain and was generally well tolerated.